ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
68 announcements
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
Zydus Lifesciences announced positive Phase II(b) clinical trial results for Saroglitazar Mg in MASH. The global study successfully met its primary endpoint of resolution of steatohepatitis.
Zydus Lifesciences Limited has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in GIFT City, Gujarat. The subsidiary has a paid-up capital of Rs. 5 Crore.
Zydus Lifesciences announced the transmission of 32,577 equity shares from Late Jasodaben Babubhai Patel to Mr. Prashant Babubhai Patel, both within the Promoter Group.
Zydus Lifesciences Limited has been assigned an overall ESG rating of 60 by ESG Risk Assessments and Insights Limited (ESGRAIL) based on independent assessment.
Zydus Lifesciences received final USFDA approval for Ascorbic Acid Injection with 180-day exclusivity. The reference brand product had annual US sales of approximately USD 11.6 million.
Zydus Lifesciences held its 31st Annual General Meeting on August 11, 2026. Shareholders approved all ordinary and special business resolutions, including the final dividend.
Zydus Lifesciences shareholders approved the re-appointment of Dr. Sharvil P. Patel as Managing Director and the appointment of Mr. Kulin S. Lalbhai as an Independent Director.
Zydus delivered robust FY27 Q1 results driven by strong India-branded formulations and U.S. generic resilience.
Zydus Lifesciences reported a contra trade violation by a designated person under SEBI PIT Regulations. The profit of Rs. 18,797 was transferred to the IEPF.
Zydus Lifesciences' subsidiary, Sentynl Therapeutics, signed an option and license agreement with Mereo BioPharma for alvelestat. The deal includes upfront and R&D payments totaling 380 Crore.
Zydus Lifesciences reported strong Q1 FY27 revenue growth of 22% YoY, driven by robust performance in India and International formulations, despite a decline in PAT and EBITDA margins.
Zydus Lifesciences Ltd reported revenue from operations of ₹8,017 Cr (+22.0% YoY) and net profit of ₹939.8 Cr (-35.9% YoY) for Q1 FY27.
Zydus Lifesciences launched REVAHALE, India's first once-daily nebulised LAMA for COPD treatment. This therapy offers 24-hour bronchodilation for patients unable to use standard handheld inhalers.
Zydus Lifesciences received final USFDA approval for Indocyanine Green for Injection with 180-day exclusivity. The reference brand had annual U.S. sales of approximately USD 125.8 million.
Zydus Lifesciences received an Establishment Inspection Report (EIR) from the USFDA for its Ahmedabad injectable facility, with a 'Voluntary Action Indicated' (VAI) classification.
Zydus Lifesciences received a demand for ₹108.54 Crore in deficient stamp duty and penalties. The company is evaluating legal remedies regarding the order.
Zydus Lifesciences received approval for a Phase III clinical trial of Desidustat for Sickle Cell Disease. The trial is conducted in collaboration with ICMR.
Zydus Lifesciences scheduled a board meeting for August 11, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Zydus Lifesciences clarified that a Delhi High Court order restricting supply of its cancer drug Ikra is not material. The company reports no material business impact.
Zydus Lifesciences submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details ESG metrics, workforce statistics, and CSR compliance for the period.
Zydus Lifesciences filed its Integrated Annual Report for FY 2025-26 and announced the AGM scheduled for August 11, 2026. The filing includes the AGM notice and report link.
Zydus Lifesciences Ltd will hold its AGM on 11 August 2026. The notice includes voting deadlines and dividend payment details.
Zydus Lifesciences announced an MoU with Apollo Hospitals to bring the Shield™ Multi‑Cancer Detection test to India. The partnership aims to expand cancer screening across the country.
Zydus Lifesciences is acquiring the API business of Sterling Biotech for Rs.84 Crore. The deal, delayed to Sep‑30‑2026, adds fermentation‑based products to its portfolio.
Zydus Lifesciences extended the closing date for its acquisition of Sterling Biotech’s API business to September 30, 2026. The deal remains pending completion.
Zydus Lifesciences formed a 50:50 joint venture in Sri Lanka. The investment is valued at up to ₹47 Crore.
Zydus Lifesciences completed the acquisition of Assertio Holdings Inc. for ₹156.35 Crore. Assertio becomes a wholly owned subsidiary, expanding Zydus' oncology portfolio.